Cargando…
A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
BACKGROUND: Adjuvant chemotherapy with platinum‐based regimens for completely resected early‐stage non‐small cell lung cancer (NSCLC) provides overall survival benefit in several clinical trials. OBJECTIVES: We conducted this prospective study to evaluate the efficacy and safety of adjuvant chemothe...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262903/ https://www.ncbi.nlm.nih.gov/pubmed/32351044 http://dx.doi.org/10.1111/1759-7714.13444 |
_version_ | 1783540711556120576 |
---|---|
author | Tanaka, Hisashi Tabe, Chiori Okumura, Fumihiko Shiratori, Toshihiro Ishioka, Yoshiko Itoga, Masamichi Taima, Kageaki Morimoto, Takeshi Kimura, Daisuke Tsushima, Takao Tasaka, Sadatomo |
author_facet | Tanaka, Hisashi Tabe, Chiori Okumura, Fumihiko Shiratori, Toshihiro Ishioka, Yoshiko Itoga, Masamichi Taima, Kageaki Morimoto, Takeshi Kimura, Daisuke Tsushima, Takao Tasaka, Sadatomo |
author_sort | Tanaka, Hisashi |
collection | PubMed |
description | BACKGROUND: Adjuvant chemotherapy with platinum‐based regimens for completely resected early‐stage non‐small cell lung cancer (NSCLC) provides overall survival benefit in several clinical trials. OBJECTIVES: We conducted this prospective study to evaluate the efficacy and safety of adjuvant chemotherapy with carboplatin and S‐1 for patients with completely resected stage II to IIIA NSCLC. METHODS: Patients with completely resected stage IIA to IIIA NSCLC were treated with four cycles of carboplatin with area under the concentration time curve of 5 mg/mL/min on day 1 plus S‐1 at 80–120 mg/bodyweight per day for two weeks, followed by one‐week rest as adjuvant chemotherapy. The primary endpoint was the completion rate of three cycles of the treatment. The secondary endpoints were safety and two‐year survival rate. RESULTS: A total of 19 patients were enrolled, until the study was terminated prematurely because of fatal pulmonary embolism in two patients. The median number of treatment cycles was three (range: 1–4). The completion rate of three cycles was 78.9% (95% confidence interval [CI]: 56.6–91.4%). Two‐year disease‐free survival rate was 57.8%. Grade 3 or 4 hematological toxicities included neutropenia (26.2%), anemia (5.2%), and thrombocytopenia (15.7%). Grade 3 or 4 nonhematological toxicities were anorexia (10.5%) and nausea (10.5%). Febrile neutropenia developed in 5.2%. In two patients (10.5%), grade five pulmonary embolism was observed, and the causal relationship with treatment could not be denied. CONCLUSIONS: Carboplatin and oral S‐1 had modest survival benefit, but this regimen was not tolerable in an adjuvant setting because fatal pulmonary embolism occurred in two patients. KEY POINTS: Carboplatin and oral S‐1 had modest survival benefit but this regimen was not tolerable. Fatal pulmonary embolism occurred in this regimen. |
format | Online Article Text |
id | pubmed-7262903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-72629032020-06-03 A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer Tanaka, Hisashi Tabe, Chiori Okumura, Fumihiko Shiratori, Toshihiro Ishioka, Yoshiko Itoga, Masamichi Taima, Kageaki Morimoto, Takeshi Kimura, Daisuke Tsushima, Takao Tasaka, Sadatomo Thorac Cancer Original Articles BACKGROUND: Adjuvant chemotherapy with platinum‐based regimens for completely resected early‐stage non‐small cell lung cancer (NSCLC) provides overall survival benefit in several clinical trials. OBJECTIVES: We conducted this prospective study to evaluate the efficacy and safety of adjuvant chemotherapy with carboplatin and S‐1 for patients with completely resected stage II to IIIA NSCLC. METHODS: Patients with completely resected stage IIA to IIIA NSCLC were treated with four cycles of carboplatin with area under the concentration time curve of 5 mg/mL/min on day 1 plus S‐1 at 80–120 mg/bodyweight per day for two weeks, followed by one‐week rest as adjuvant chemotherapy. The primary endpoint was the completion rate of three cycles of the treatment. The secondary endpoints were safety and two‐year survival rate. RESULTS: A total of 19 patients were enrolled, until the study was terminated prematurely because of fatal pulmonary embolism in two patients. The median number of treatment cycles was three (range: 1–4). The completion rate of three cycles was 78.9% (95% confidence interval [CI]: 56.6–91.4%). Two‐year disease‐free survival rate was 57.8%. Grade 3 or 4 hematological toxicities included neutropenia (26.2%), anemia (5.2%), and thrombocytopenia (15.7%). Grade 3 or 4 nonhematological toxicities were anorexia (10.5%) and nausea (10.5%). Febrile neutropenia developed in 5.2%. In two patients (10.5%), grade five pulmonary embolism was observed, and the causal relationship with treatment could not be denied. CONCLUSIONS: Carboplatin and oral S‐1 had modest survival benefit, but this regimen was not tolerable in an adjuvant setting because fatal pulmonary embolism occurred in two patients. KEY POINTS: Carboplatin and oral S‐1 had modest survival benefit but this regimen was not tolerable. Fatal pulmonary embolism occurred in this regimen. John Wiley & Sons Australia, Ltd 2020-04-29 2020-06 /pmc/articles/PMC7262903/ /pubmed/32351044 http://dx.doi.org/10.1111/1759-7714.13444 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Tanaka, Hisashi Tabe, Chiori Okumura, Fumihiko Shiratori, Toshihiro Ishioka, Yoshiko Itoga, Masamichi Taima, Kageaki Morimoto, Takeshi Kimura, Daisuke Tsushima, Takao Tasaka, Sadatomo A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer |
title | A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer |
title_full | A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer |
title_fullStr | A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer |
title_full_unstemmed | A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer |
title_short | A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer |
title_sort | pilot study of adjuvant chemotherapy with carboplatin and oral s‐1 for patients with completely resected stage ii to iiia non‐small cell lung cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262903/ https://www.ncbi.nlm.nih.gov/pubmed/32351044 http://dx.doi.org/10.1111/1759-7714.13444 |
work_keys_str_mv | AT tanakahisashi apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT tabechiori apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT okumurafumihiko apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT shiratoritoshihiro apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT ishiokayoshiko apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT itogamasamichi apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT taimakageaki apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT morimototakeshi apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT kimuradaisuke apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT tsushimatakao apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT tasakasadatomo apilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT tanakahisashi pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT tabechiori pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT okumurafumihiko pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT shiratoritoshihiro pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT ishiokayoshiko pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT itogamasamichi pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT taimakageaki pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT morimototakeshi pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT kimuradaisuke pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT tsushimatakao pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer AT tasakasadatomo pilotstudyofadjuvantchemotherapywithcarboplatinandorals1forpatientswithcompletelyresectedstageiitoiiianonsmallcelllungcancer |